ARK Invest CoreWeave stock purchase follows a sharp drop after Strong earnings, highlighting growth and other strategic moves.
Article produced with artificial intelligence systems and published under the editorial responsibility of Amelia Tomasicchio. How we work
Cathie Wood’s ARK Invest bought 283,022 shares of CoreWeave stock on November 12, 2026, as the shares fell following an earnings-driven rally. On the very day ARK offloaded about $10 million worth of Palantir Technologies stock and $4.2 million in Amazon shares, it made this purchase, which carried a value of roughly $16 million to $17 million depending on the pricing basis used.
Summary
Key takeaways
- ARK added CoreWeave shares after a 6.9% decline.
- CoreWeave lifted its 2026 revenue outlook to $13 billion–$13.3 billion.
- Palantir beat earnings estimates, but contract-value growth slowed.
- ARK also bought biotechnology, aviation and defense stocks.
ARK Invest adds CoreWeave stock after sharp price swings
ARK split its CoreWeave purchase between the ARKK and ARKW funds. The stock dropped 6.9% on November 12, following a 24.7% surge on November 11 after the company’s third-quarter results.
CoreWeave reported quarterly revenue of $3.66 billion, up 168% from a year earlier. It raised its 2026 revenue forecast to $13 billion–$13.3 billion and lifted its year-end annual recurring revenue outlook to $20 billion–$21 billion. Its backlog reached $132.5 billion.
The company also forecast adjusted operating income of $1.275 billion–$1.375 billion. That compared with the $1.07 billion expected by analysts surveyed by Visible Alpha, while analysts polled by LSEG had forecast 2026 revenue of $12.86 billion.
In addition to those projections, CoreWeave expects to collect $9 billion in customer prepayments and deposits within the coming three months. According to CEO Michael Intrator, this funding will help finance the buildout and scaling of the AI infrastructure and software that customers require, while contract-backed financing was also cited as another avenue supporting growth.
Earnings news prompts Palantir and Amazon sales
On November 12, ARK offloaded 58,339 Palantir shares through its ARKK and ARKW funds, a move worth roughly $10 million, coming after the company posted results that topped both revenue and adjusted-earnings projections.
Palantir’s third-quarter revenue climbed 96% to reach $2.31 billion, surpassing the $2.18 billion Wall Street consensus, while adjusted earnings came in at $0.44 per share versus the $0.41 forecast.
Palantir raised its 2026 revenue guidance to approximately $8.53 billion, implying roughly 91% annual growth. But total contract value increased only 6% to $2.92 billion, down from 49% growth in the preceding quarter. Its shares had fallen nearly 18% over the past month.
ARK’s Amazon stock sales included 15,941 shares through ARKK on November 12, worth approximately $4.2 million. Combined with 10,968 shares sold on November 10, the two transactions totaled 26,909 shares worth about $7.3 million.
Other purchases span biotech, aviation and defense
ARK’s November 12 purchases extended beyond CoreWeave stock to Twist Bioscience, Archer Aviation, Kratos Defense & Security Solutions, Rocket Lab and Scribe Therapeutics.
The firm bought 72,834 Twist Bioscience shares for $8.93 million through ARKK and ARKG. It also purchased 180,561 Archer Aviation shares across three funds for $877,526, continuing a week of buying.
Further purchases comprised 46,521 shares of Kratos Defense & Security Solutions worth $1.71 million, 15,114 shares of Rocket Lab valued at approximately $1 million, and 39,090 shares of Scribe Therapeutics costing $659,057.
TipRanks data assigns Amazon a Strong Buy consensus, while CoreWeave and Palantir carry Moderate Buy ratings. Based on average analyst price targets, the implied upside stands at 83.9% for CoreWeave, 33.5% for Palantir, and 21.5% for Amazon.
Article produced with the assistance of artificial intelligence and reviewed by the editorial team.
